Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 427,629 shares of CYTK, which is worth approximately $18.5 Million. The most recent transaction as insider was on Oct 30, 2023, when has been sold 12,500 shares (Common Stock) at a price of $32.17 per share, resulting in proceeds of $402,125. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 428K

6.02% 3M change

7.28% 12M change

Total Value Held $18.5 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 30 2023	SELL Open market or private sale	$402,125 $32.17 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Oct 30 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Oct 16 2023	SELL Open market or private sale	$421,250 $33.7 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Oct 16 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Oct 06 2023	SELL Open market or private sale	$375,000 $30.0 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Oct 06 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Sep 13 2023	SELL Open market or private sale	$436,250 $34.9 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Sep 13 2023	BUY Exercise of conversion of derivative security	$83,375 $6.67 p/Share	12,500 Added 2.68%	453,917 Common Stock
Aug 25 2023	SELL Open market or private sale	$424,875 $33.99 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Aug 25 2023	BUY Exercise of conversion of derivative security	$91,500 $7.32 p/Share	12,500 Added 2.68%	453,917 Common Stock
Aug 11 2023	SELL Open market or private sale	$404,624 $32.37 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Aug 11 2023	BUY Exercise of conversion of derivative security	$110,125 $8.81 p/Share	12,500 Added 2.75%	442,209 Common Stock
Aug 01 2023	SELL Open market or private sale	$407,875 $32.63 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Aug 01 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.74%	443,226 Common Stock
Jul 13 2023	SELL Open market or private sale	$441,000 $35.28 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Jul 13 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,917 Common Stock
Jul 03 2023	SELL Open market or private sale	$407,500 $32.6 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Jul 03 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,917 Common Stock
Jun 12 2023	SELL Open market or private sale	$463,250 $37.06 p/Share	12,500 Reduced 2.75%	441,417 Common Stock
Jun 12 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,917 Common Stock
May 31 2023	SELL Open market or private sale	$470,875 $37.67 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
May 31 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
May 16 2023	SELL Open market or private sale	$467,624 $37.41 p/Share	12,500 Reduced 2.76%	441,058 Common Stock
May 16 2023	BUY Exercise of conversion of derivative security	$120,625 $9.65 p/Share	12,500 Added 2.68%	453,558 Common Stock
Apr 28 2023	SELL Open market or private sale	$471,000 $37.68 p/Share	12,500 Reduced 2.76%	441,058 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account